Do analysts prefer AZN or BMK?

AstraZeneca presently has a consensus price target of £152.17, indicating a potential upside of 24.32%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Benchmark. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Benchmark 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, AZN or BMK?

AstraZeneca has higher revenue and earnings than Benchmark. AstraZeneca is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca £61.37B 3.09 £8.71B £668.00 18.32 Benchmark £79.16M 1,189.43 -£39.55M £0.06 246,774.19

Is AZN or BMK more profitable?

AstraZeneca has a net margin of 17.02% compared to Benchmark's net margin of -43.67%. AstraZeneca's return on equity of 21.68% beat Benchmark's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.02% 21.68% 7.68% Benchmark -43.67% -15.96% -1.07%

Does the media prefer AZN or BMK?

In the previous week, AstraZeneca had 7 more articles in the media than Benchmark. MarketBeat recorded 8 mentions for AstraZeneca and 1 mentions for Benchmark. Benchmark's average media sentiment score of 0.67 beat AstraZeneca's score of -0.31 indicating that Benchmark is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Benchmark 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, AZN or GSK?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca £61.37B 3.09 £8.71B £668.00 18.32 GSK £33.20B 2.31 £2.50B £117.80 16.29

Is AZN or GSK more profitable?

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.02% 21.68% 7.68% GSK 14.52% 28.35% 9.56%

Does the media refer more to AZN or GSK?

In the previous week, AstraZeneca had 3 more articles in the media than GSK. MarketBeat recorded 8 mentions for AstraZeneca and 5 mentions for GSK. GSK's average media sentiment score of 0.39 beat AstraZeneca's score of -0.31 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral GSK 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DPH or AZN?

AstraZeneca has a consensus target price of £152.17, suggesting a potential upside of 24.32%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Dechra Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dechra Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media prefer HIK or AZN?

In the previous week, AstraZeneca had 7 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 8 mentions for AstraZeneca and 1 mentions for Hikma Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat AstraZeneca's score of -0.31 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AstraZeneca 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate AZN or INDV?

AstraZeneca currently has a consensus target price of £152.17, indicating a potential upside of 24.32%. Given AstraZeneca's stronger consensus rating and higher possible upside, research analysts clearly believe AstraZeneca is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, AZN or INDV?

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca £61.37B 3.09 £8.71B £668.00 18.32 Indivior £1.40B 1.38 -£2.36M -£1.21 N/A

Is AZN or INDV more profitable?

AstraZeneca has a net margin of 17.02% compared to Indivior's net margin of 11.44%. AstraZeneca's return on equity of 21.68% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.02% 21.68% 7.68% Indivior 11.44% -23.90% 2.37%

Does the media refer more to AZN or INDV?

In the previous week, AstraZeneca had 7 more articles in the media than Indivior. MarketBeat recorded 8 mentions for AstraZeneca and 1 mentions for Indivior. Indivior's average media sentiment score of 0.75 beat AstraZeneca's score of -0.31 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AstraZeneca (AZN) Competitors

£122.40 +152.00 (+1.26%)

As of 08/21/2026 12:28 PM Eastern

Compare

AZN vs. BMK, GSK, DPH, HIK, and INDV

Should you buy AstraZeneca stock or one of its competitors? AstraZeneca's main competitors and comparable companies include Benchmark (BMK), GSK (GSK), Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does AstraZeneca compare to Benchmark?

AstraZeneca (LON:AZN) and Benchmark (LON:BMK) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

AstraZeneca presently has a consensus price target of £152.17, indicating a potential upside of 24.32%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Benchmark.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Benchmark	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AstraZeneca has a beta of 0.211, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Benchmark has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

67.8% of AstraZeneca shares are held by institutional investors. Comparatively, 13.3% of Benchmark shares are held by institutional investors. 0.2% of AstraZeneca shares are held by insiders. Comparatively, 63.7% of Benchmark shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AstraZeneca has a net margin of 17.02% compared to Benchmark's net margin of -43.67%. AstraZeneca's return on equity of 21.68% beat Benchmark's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
Benchmark	-43.67%	-15.96%	-1.07%

AstraZeneca has higher revenue and earnings than Benchmark. AstraZeneca is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	3.09	£8.71B	£668.00	18.32
Benchmark	£79.16M	1,189.43	-£39.55M	£0.06	246,774.19

In the previous week, AstraZeneca had 7 more articles in the media than Benchmark. MarketBeat recorded 8 mentions for AstraZeneca and 1 mentions for Benchmark. Benchmark's average media sentiment score of 0.67 beat AstraZeneca's score of -0.31 indicating that Benchmark is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Benchmark	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AstraZeneca beats Benchmark on 11 of the 16 factors compared between the two stocks.

How does AstraZeneca compare to GSK?

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

AstraZeneca has a beta of 0.211, suggesting that its share price is 79% less volatile than the broader market. Comparatively, GSK has a beta of 0.295, suggesting that its share price is 71% less volatile than the broader market.

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
GSK	14.52%	28.35%	9.56%

AstraZeneca currently has a consensus price target of £152.17, suggesting a potential upside of 24.32%. GSK has a consensus price target of GBX 2,048.57, suggesting a potential upside of 6.78%. Given AstraZeneca's stronger consensus rating and higher probable upside, equities analysts clearly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, AstraZeneca had 3 more articles in the media than GSK. MarketBeat recorded 8 mentions for AstraZeneca and 5 mentions for GSK. GSK's average media sentiment score of 0.39 beat AstraZeneca's score of -0.31 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.6%. GSK pays an annual dividend of GBX 67 per share and has a dividend yield of 3.5%. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. GSK pays out 56.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	3.09	£8.71B	£668.00	18.32
GSK	£33.20B	2.31	£2.50B	£117.80	16.29

67.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 56.9% of GSK shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by insiders. Comparatively, 0.2% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

AstraZeneca beats GSK on 12 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Dechra Pharmaceuticals?

Dechra Pharmaceuticals (LON:DPH) and AstraZeneca (LON:AZN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

AstraZeneca has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A
AstraZeneca	£61.37B	3.09	£8.71B	£668.00	18.32

AstraZeneca has a net margin of 17.02% compared to Dechra Pharmaceuticals' net margin of -3.66%. AstraZeneca's return on equity of 21.68% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%
AstraZeneca	17.02%	21.68%	7.68%

In the previous week, AstraZeneca had 8 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 8 mentions for AstraZeneca and 0 mentions for Dechra Pharmaceuticals. Dechra Pharmaceuticals' average media sentiment score of 0.00 beat AstraZeneca's score of -0.31 indicating that Dechra Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Dechra Pharmaceuticals	Neutral
AstraZeneca	Neutral

105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 9.3% of Dechra Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dechra Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.211, meaning that its share price is 79% less volatile than the broader market.

AstraZeneca has a consensus target price of £152.17, suggesting a potential upside of 24.32%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.6%. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

AstraZeneca beats Dechra Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to Hikma Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and AstraZeneca (LON:AZN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 22.0% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of AstraZeneca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals presently has a consensus price target of GBX 2,060, suggesting a potential upside of 25.92%. AstraZeneca has a consensus price target of £152.17, suggesting a potential upside of 24.32%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than AstraZeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

AstraZeneca has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	1.00	£353.21M	£181.00	9.04
AstraZeneca	£61.37B	3.09	£8.71B	£668.00	18.32

Hikma Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.211, meaning that its share price is 79% less volatile than the broader market.

AstraZeneca has a net margin of 17.02% compared to Hikma Pharmaceuticals' net margin of 11.31%. AstraZeneca's return on equity of 21.68% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
AstraZeneca	17.02%	21.68%	7.68%

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.1%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.6%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, AstraZeneca had 7 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 8 mentions for AstraZeneca and 1 mentions for Hikma Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat AstraZeneca's score of -0.31 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AstraZeneca	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Hikma Pharmaceuticals and AstraZeneca tied by winning 9 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Indivior?

AstraZeneca (LON:AZN) and Indivior (LON:INDV) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

AstraZeneca has a net margin of 17.02% compared to Indivior's net margin of 11.44%. AstraZeneca's return on equity of 21.68% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
Indivior	11.44%	-23.90%	2.37%

In the previous week, AstraZeneca had 7 more articles in the media than Indivior. MarketBeat recorded 8 mentions for AstraZeneca and 1 mentions for Indivior. Indivior's average media sentiment score of 0.75 beat AstraZeneca's score of -0.31 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	3.09	£8.71B	£668.00	18.32
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

67.8% of AstraZeneca shares are held by institutional investors. Comparatively, 86.0% of Indivior shares are held by institutional investors. 0.2% of AstraZeneca shares are held by company insiders. Comparatively, 3.4% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AstraZeneca has a beta of 0.211, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

AstraZeneca currently has a consensus target price of £152.17, indicating a potential upside of 24.32%. Given AstraZeneca's stronger consensus rating and higher possible upside, research analysts clearly believe AstraZeneca is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.6%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

AstraZeneca beats Indivior on 14 of the 18 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	AstraZeneca	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£189.83B	£12.57B	£7.37B	£2.54B
Dividend Yield	1.95%	2.61%	2.53%	6.17%
P/E Ratio	18.32	789.80	272.60	367.57
Price / Sales	3.09	764.53	624.33	83,481.74
Price / Cash	38.89	96.77	78.62	27.89
Price / Book	4.65	11.89	13.05	7.19
Net Income	£8.71B	£2.81B	£3.47B	£5.89B
7 Day Performance	6.81%	1.77%	2.09%	0.30%
1 Month Performance	-3.53%	3.85%	6.64%	3.31%
1 Year Performance	2.31%	6.56%	25.02%	22.13%

AstraZeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN AstraZeneca	4.1307 of 5 stars	£122.40 +1.3%	£152.17 +24.3%	+2.3%	£189.83B	£61.37B	18.32	83,500	Analyst Forecast High Trading Volume
BMK Benchmark	N/A	£153 -0.6%	N/A	-12.6%	£94.15B	£79.16M	246,774.19	823	News Coverage
GSK GSK	2.7233 of 5 stars	GBX 1,918.50 -0.1%	GBX 2,048.57 +6.8%	+29.7%	£76.85B	£33.20B	16.29	70,212
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HIK Hikma Pharmaceuticals	4.5915 of 5 stars	GBX 1,636 +0.7%	GBX 2,060 +25.9%	-10.9%	£3.42B	£3.42B	9.04	9,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AZN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Competitors

AZN vs. BMK, GSK, DPH, HIK, and INDV

How does AstraZeneca compare to Benchmark?

Summary

How does AstraZeneca compare to GSK?

Summary

How does AstraZeneca compare to Dechra Pharmaceuticals?

Summary

How does AstraZeneca compare to Hikma Pharmaceuticals?

Summary

How does AstraZeneca compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AstraZeneca (AZN) Competitors

AZN vs. BMK, GSK, DPH, HIK, and INDV

How does AstraZeneca compare to Benchmark?

Do analysts prefer AZN or BMK?

Which has more volatility & risk, AZN or BMK?

Do insiders & institutionals believe in AZN or BMK?

Is AZN or BMK more profitable?

Which has higher earnings & valuation, AZN or BMK?

Does the media prefer AZN or BMK?

Summary

How does AstraZeneca compare to GSK?

Which has more volatility and risk, AZN or GSK?

Is AZN or GSK more profitable?

Do analysts rate AZN or GSK?

Does the media refer more to AZN or GSK?

Is AZN or GSK a better dividend stock?

Which has stronger valuation & earnings, AZN or GSK?

Do insiders & institutionals believe in AZN or GSK?

Summary

How does AstraZeneca compare to Dechra Pharmaceuticals?

Which has stronger valuation & earnings, DPH or AZN?

Is DPH or AZN more profitable?

Does the media prefer DPH or AZN?

Do insiders and institutionals hold more shares of DPH or AZN?

Which has more volatility & risk, DPH or AZN?

Do analysts rate DPH or AZN?

Is DPH or AZN a better dividend stock?

Summary

How does AstraZeneca compare to Hikma Pharmaceuticals?

Do institutionals and insiders hold more shares of HIK or AZN?

Do analysts prefer HIK or AZN?

Which has stronger earnings & valuation, HIK or AZN?

Which has more volatility & risk, HIK or AZN?

Is HIK or AZN more profitable?

Is HIK or AZN a better dividend stock?

Does the media prefer HIK or AZN?

Summary

How does AstraZeneca compare to Indivior?

Is AZN or INDV more profitable?

Does the media refer more to AZN or INDV?

Which has higher valuation & earnings, AZN or INDV?

Do insiders & institutionals believe in AZN or INDV?

Which has more volatility & risk, AZN or INDV?

Do analysts rate AZN or INDV?

Is AZN or INDV a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools